1.Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies.
Zhenan DENG ; Meiling JIN ; Changxing OU ; Wei JIANG ; Jianping ZHAO ; Xiaoxia LIU ; Shenghua SUN ; Huaping TANG ; Bei HE ; Shaoxi CAI ; Ping CHEN ; Penghui WU ; Yujing LIU ; Jian KANG ; Yunhui ZHANG ; Mao HUANG ; Jinfu XU ; Kewu HUANG ; Qiang LI ; Xiangyan ZHANG ; Xiuhua FU ; Changzheng WANG ; Huahao SHEN ; Lei ZHU ; Guochao SHI ; Zhongmin QIU ; Zhongguang WEN ; Xiaoyang WEI ; Wei GU ; Chunhua WEI ; Guangfa WANG ; Ping CHEN ; Lixin XIE ; Jiangtao LIN ; Yuling TANG ; Zhihai HAN ; Kian Fan CHUNG ; Qingling ZHANG ; Nanshan ZHONG
Chinese Medical Journal 2023;136(2):230-232
2.Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial.
Yifan CHANG ; Xianzhi ZHAO ; Yutian XIAO ; Shi YAN ; Weidong XU ; Ye WANG ; Huojun ZHANG ; Shancheng REN
Frontiers of Medicine 2023;17(2):231-239
To evaluate the safety and efficacy of neoadjuvant radiohormonal therapy for oligometastatic prostate cancer (OMPC), we conducted a 3 + 3 dose escalation, prospective, phase I/II, single-arm clinical trial (CHiCTR1900025743), in which long-term neoadjuvant androgen deprivation was adopted 1 month before radiotherapy, comprising intensity modulated radiotherapy to the pelvis, and stereotactic body radiation therapy to all extra-pelvic bone metastases for 4-7 weeks, at 39.6, 45, 50.4, and 54 Gy. Robotic-assisted radical prostatectomy was performed after 5-14 weeks. The primary outcome was treatment-related toxicities and adverse events; secondary outcomes were radiological treatment response, positive surgical margin (pSM), postoperative prostate-specific antigen (PSA), pathological down-grading and tumor regression grade, and survival parameters. Twelve patients were recruited from March 2019 to February 2020, aging 66.2 years in average (range, 52-80). Median baseline PSA was 62.0 ng/mL. All underwent RARP successfully without open conversions. Ten patients recorded pathological tumor down-staging (83.3%), and 5 (41.7%) with cN1 recorded negative regional lymph nodes on final pathology. 66.7% (8/12) recorded tumor regression grading (TRG) -I and 25% (3/12) recorded TRG-II. Median follow-up was 16.5 months. Mean radiological progression-free survival (RPFS) was 21.3 months, with 2-year RPFS of 83.3%. In all, neoadjuvant radiohormonal therapy is well tolerated for oligometastatic prostate cancer.
Male
;
Humans
;
Prostatic Neoplasms/radiotherapy*
;
Prostate-Specific Antigen/therapeutic use*
;
Neoadjuvant Therapy
;
Androgen Antagonists/therapeutic use*
;
Prospective Studies
3.Dynamic disease manifestations among individuals infected with SARS-CoV-2 Omicron variant.
Peiqin WANG ; Xinwei FENG ; Zhiwen SHI ; Zimao JIANG ; Luping WANG ; Xin GAO ; Hui QI ; Min CHEN ; Jian WANG ; Weifen XIE
Chinese Medical Journal 2023;136(22):2768-2770
Humans
;
COVID-19
;
SARS-CoV-2
5.A comparison of perioperative outcomes between extraperitoneal robotic single-port and multiport radical prostatectomy with the da Vinci Si Surgical System.
Guan-Qun JU ; Zhi-Jun WANG ; Jia-Zi SHI ; Zong-Qin ZHANG ; Zhen-Jie WU ; Lei YIN ; Bing LIU ; Lin-Hui WANG ; Dong-Liang XU
Asian Journal of Andrology 2021;23(6):640-647
To evaluate outcomes between extraperitoneal robotic single-port radical prostatectomy (epR-spRP) and extraperitoneal robotic multiport radical prostatectomy (epR-mpRP) performed with the da Vinci Si Surgical System, comparison was performed between 30 single-port (SP group) and 26 multiport (MP group) cases. Comparisons included operative time, estimated blood loss (EBL), hospital stay, peritoneal violation, pain scores, scar satisfaction, continence, and erectile function. The median operation time and EBL were not different between the two groups. In the SP group, the median operation time of the first 10 patients was obviously longer than that of the latter 20 patients (P < 0.001). The median postoperative hospital stay in the SP group was shorter than that in the MP group (P < 0.001). The rate of peritoneal damage in the SP group was less than that in the MP group (P = 0.017). The pain score and overall need for pain medications in the SP group were lower than those in the MP group (P < 0.001 and P = 0.015, respectively). Patients in the SP group were more satisfied with their scars than those in the MP group 3 months postoperatively (P = 0.007). At 3 months, the cancer control, recovery of erectile function, and urinary continence rates were similar between the two groups. It is safe and feasible to perform epR-spRP using the da Vinci Si surgical system. Therefore, epR-spRP can be a treatment option for localized prostate cancer. Although epR-spRP still has a learning curve, it has advantages for postoperative pain and self-assessed cosmesis. In the absence of the single-port robotic surgery platform, we can still provide minimally invasive surgery for patients.
Aged
;
Blood Loss, Surgical/statistics & numerical data*
;
Humans
;
Male
;
Middle Aged
;
Outcome Assessment, Health Care/statistics & numerical data*
;
Perioperative Medicine/statistics & numerical data*
;
Prostatectomy/methods*
;
Prostatic Neoplasms/surgery*
;
Quality Assurance, Health Care/statistics & numerical data*
;
Robotic Surgical Procedures/statistics & numerical data*
6. Analysis of the effective components and mechanism of Yufang Fangji II for prevention of COVID-19 based on UHPLC-Q-TOF/MS and network pharmacology
Guangyang JIAO ; Doudou HUANG ; Yong CHEN ; Deduo XU ; Wansheng CHEN ; Feng ZHANG ; Tianyi YU ; Bolong WANG ; Shi QIU ; Wansheng CHEN
Chinese Journal of Clinical Pharmacology and Therapeutics 2021;26(10):1127-1145
AIM: The main chemical components of Yufang Fangji II (Hubei Fang) of COVID-19 were studied systematically and combined with network pharmacology to provide a reference for the study of its effective substances. METHODS: Ultra high-performance liquid chromatography quadrupole time of flight mass spectrometry (UHPLC-Q-TOF/MS) was applied to identify the absorbed components of the prescription in rat plasma. TCMSP database and Swiss Target Prediction data platform were used to predict the target of the identified blood components, and network visualization software Cytoscape 3.7.2 was used draw the association network diagram, and GO enrichment analysis and KEGG pathway enrichment analysis were conducted for the key targets. With the help of CB-Dock online molecular docking platform, the molecular docking of key targets and blood entering compounds was carried out, and the docking combination with good affinity value was displayed by ligplot software to verify the preventive effect of Yufang Fangji II on COVID-19. RESULTS: A total of 52 chemical components identified in the prescription, in which 13 components were absorbed in the rat plasma as the prototype, and they were from Astragalus membranaceus, Atractylodes macrocephala, Saposhnikoviae Radix, Lonicerae Japonicae Flos, and Citri Reticulatae Pericarpium, respectively. These compounds were recognized to act on 17 core targets, including mapk3, TNF and other targets related to inflammation, MPO and other targets related to oxidative stress, VEGFR, KDR and other targets related to vascular endothelium. The results of molecular docking showed that the absorbed components had good binding activity with the key targets. CONCLUSION: Compounds in Yufang Fangji II are involved in regulating inflammation, oxidative stress, vascular and cellular physiological activities, which have preventive effects on COVID-19 through regulating IL-17, PI3K Akt, MAPK and other pathways.
7.Study on the anti-RSV activity and mechanism of Mentha haplocalyx Briq.
Chenxiao SHI ; Jiaxin XU ; Hao GUO ; Changzheng ZHOU
International Journal of Traditional Chinese Medicine 2020;42(6):562-566
Objective:To explore the inhibitory effects of Mentha haplocalyx Briq. With different extraction methods on respiratory syncytial virus (RSV) in vitro and antiviral mechanism of it seffective parts. Methods:By using the virus infection model in vitro to detect the cytopathic effect (CPE) of the anti-RSV effect of Mentha haplocalyx Briq. in vitro. Make the anti-RSV therapeutic index (TI) in vitroas the index to screen the extraction method of mint and the macro-porous adsorption resin, so as to determine the best extraction method, and the best macroporous adsorption resin was used for separation and purification. Elution with different concentrations of eluent was used to determine the effective parts of Mentha haplocalyx Briq. resisting RSV. The antiviral mechanism was analyzed by different administration methods. Results:The supernatant of Mint after water extraction and alcohol precipitation had the strongest inhibitory effect on RSV, with TI value of 37.58; HPD100 resin had the best separation and purification effect on the supernatant, and 25% ethanol elution site had the best effect, and the TI value was 57.8. The effective substances were determined to be polyphenols by physicochemical identification reaction. After the effective parts are mixed with the virus, the antiviral experiment is the best.Conclusions:The supernatant of mint after water extraction and alcohol precipitation was adsorbed by HPD100, and 25% ethanol eluent had the best anti-RSV effect, with preventive and therapeutic effects.
8.Molecular genetics of medicinal plants, past achievement, and new era.
Shi-Lin CHEN ; Wei SUN ; Wen-Guang WU ; Wan-Sheng CHEN ; Ying WANG ; Yang DONG ; Yi-Fei LIU ; Zhi-Chao XU ; Chao SUN ; Qing-Gang YIN ; Yong-Qing LI ; Ming LUO ; Ying XIAO ; Hui-Hua WAN
China Journal of Chinese Materia Medica 2020;45(23):5577-5588
Unraveling the genetic basis of medicinal plant metabolism and developmental traits is a long-standing goal for pharmacologists and plant biologists. This paper discusses the definition of molecular genetics of medicinal plants, which is an integrative discipline with medicinal plants as the research object. This discipline focuses on the heredity and variation of medicinal plants, and elucidates the relationship between the key traits of medicinal plants(active compounds, yield, resistance, etc.) and genotype, studies the structure and function, heredity and variation of medicinal plant genes mainly at molecular level, so as to reveal the molecular mechanisms of transmission, expression and regulation of genetic information of medicinal plants. Specifically, we emphasize on three major aspects of this discipline.(1)Individual and population genetics of medicinal plants, this part mainly highlights the genetic mechanism of the domestication, the individual genomics at the species level, and the formation of genetic diversity of medicinal plants.(2)Elucidation of biosynthetic pathways of active compounds and their evolutionary significance. This part summarizes the biosynthesis, diversity and molecular evolution of active compounds in medicinal plants.(3) Molecular mechanisms that shaping the key agronomic traits by internal and external factors. This part focuses on the accumulation and distribution of active compounds within plants and the regulation of metabolic network by environmental factors. Finally, we prospect the future direction of molecular genetics of medicinal plants based on the rapid development of multi-omics technology, as well as the application of molecular genetics in the future strategies to achieve conservation and breeding of medicinal plants and efficient biosynthesis of active compounds.
Biosynthetic Pathways
;
Genomics
;
Molecular Biology
;
Plant Breeding
;
Plants, Medicinal
9.Collaborations of Industry, Academia, Research and Application Improve the Healthy Development of Medical Imaging Artificial Intelligence Industry in China.
Chinese Medical Sciences Journal 2019;34(2):84-88
In recent years, artificial intelligence (AI) has developed rapidly in the field of medical imaging. However, the collaborations among hospitals, research institutes and enterprises are insufficient at the present, and there are various issues in technological transformation and value landing of products in this area. To solve the core problems in the developmental path of medical imaging AI, the Chinese Innovative Alliance of Industry, Education, Research and Application of Artificial Intelligence for Medical Imaging compiled the . This article introduces the current status of collaboration, the clinical demands for medical imaging AI technique, and the key points in AI technology transformation: robustness, usability and security. We are facing challenges of lacking industry standards, data desensitization standard, assessment system, as well as corresponding regulations and policies to realize the application values of AI products in medical imaging. Further development of AI in medical imaging requires breakthroughs of the core algorithm, deep involvement of doctors, input from capitals, patience from societies, and most importantly, the resolutions from government for multiple difficulties in links of landing the technology.
10.Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma.
Hai-Min CHEN ; Wei WEI ; Rong PENG ; Hao-Tian SHI ; Xiao-Ling CHEN ; Li-Xia WU ; Nian ZHOU ; Fan ZHOU
Journal of Experimental Hematology 2019;27(1):110-114
OBJECTIVE:
To evaluate the prognostic value of R-ISS staging system in patients with newly diagnosed multiple myeloma (NDMM).
METHODS:
The Chinical data of 412 patients with NDMM in our hospital from May 2010 to May 2016 were retrospectively analyzed. All the patients received conventional chemotherapy or thalidomide or bortezomib-based chemotherapy. All the patients with NDMM were divided into R-ISS-Ⅰ, R-ISS-Ⅱ and R-ISS-Ⅲ groups according to R-ISS staging system on the basis of ISS staging system, cytogenetics and LDH level. The progression-free survival (PFS) time and overall survival(OS) of different groups were compared.
RESULTS:
Among all 412 patients, 76 were rated as R-ISS-Ⅰ, 259 as R-ISS-Ⅱ and 77 as R-ISS-Ⅲ. The median PFS time in 3 groups were 44, 25 and 14 months respectively (P<0.01). The median OS time of the 3 groups were not reached 54 and 25 months respectively (P<0.01). Further analysis also found that statistically different survival associated with different R-ISS groups in the conventional chemotherapy group (P<0.05), bortezomib-based chemotherapy group (P<0.01), thalidomide-based chemotherapy group (P<0.01), transplantation group (P<0.05), different-age stratified group (≤65y P<0.01, 66-75y P<0.01,≥76y P<0.01), damaged renal function group (P<0.01) and extramedullary infiltration group (P<0.01).
CONCLUSION
PFS and OS in the patients with multiple myeloma were different among three distrinct R-ISS stages. The R-ISS staging system has important clinical significance for the prognosis evaluation of multiple myeloma.
Antineoplastic Combined Chemotherapy Protocols
;
Bortezomib
;
Humans
;
Multiple Myeloma
;
diagnosis
;
Neoplasm Staging
;
Prognosis
;
Retrospective Studies
;
Thalidomide
;
Treatment Outcome

Result Analysis
Print
Save
E-mail